Alzheimer's vaccine results boost Elan, Wyeth

Published on Tuesday 17 June 2008 - 19:02

Summary :
Wyeth and Elan's shares were up today as the companies announced potentially promising results from a phase II trial of bapineuzumab, an Alzheimer's vaccine. The study did not attain statistical...
Read more

Information source

http://www.fiercebiotech.com/news/frontpage

Website description
Get the latest news on the biotech industry, biotech companies, FDA approval and clinical research. Sign up today for the biotech industry

Articles published on this website : 1 / 7 days - 6 / 30 days

Satori gains $22M to push Alzheimer's work Myriad's Meldrum picked as best biotech CEO Lundbeck preps Phase III trials for alcoholism Elan closes sites, cuts jobs Elan's Martin: Worst biotech CEO?

Other articles published on other websites on the same day

Elan shares climb to six - year high after Alzheimer's drug study shows some positive results http://www.pharmiweb.com/ Grape seed extract may reduce Alzheimer's cognitive decline http://www.scienceblog.com/ UCSF and YouTube Partner Up for Education on Dementia http://www.medgadget.com/ Progression of Mild Cognitive Impairment Visualized on PET http://www.medscape.com/ Thursday, June 26 http://www.hsvvoice.com/ Wyeth's Alzheimer's drug shows promise http://foodconsumer.org/ Wyeth Shares Rises on Promising Study of Alzheimer’s Drug http://www.nytimes.com/ High hopes for new Alzheimer's drug http://www.marketplace.org/ New Drug Assists Some Alzheimer Patients http://www.overthelimit.info/ Elan, Wyeth Gain Data From Alzheimers Treatment Study http://www.pharmiweb.com/